AAV Infection: Protection from Cancer

Human Gene Therapy

Volumn 28, Issue 4, 2017, Pages 323-327

  Srivastava, Arun ^a   Carter, Barrie J ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b BIOMARIN PHARMACEUTICAL INC   (United States)

Author keywords

DNA integration; liver cancer; recombinant AAV vectors; wild type AAV2

Indexed keywords

ADENO ASSOCIATED VIRUS VECTOR; VIRUS DNA;

ADENO ASSOCIATED VIRUS 2; ARTICLE; DNA INTEGRATION; HUMAN; MALIGNANT NEOPLASM; NONHUMAN; PARVOVIRUS INFECTION; VIRUS GENOME; WILD TYPE; ANIMAL; CARCINOMA, HEPATOCELLULAR; CLASSIFICATION; CLINICAL TRIAL (TOPIC); DEPENDOPARVOVIRUS; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETICS; LIVER NEOPLASMS; MOUSE; THERAPEUTIC USE;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS AS TOPIC; DEPENDOVIRUS; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HUMANS; LIVER NEOPLASMS; MICE;

EID: 85018513551     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2016.147     Document Type: Article

References (70)

1. Nault JC, Datta S, Imbeaud S, et al. Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. Nat Genet 2015;47: 1187-1193.
2. Berns KI, Byrne BJ, Flotte TR, et al. Adenoassociated virus type 2 and hepatocellular carcinoma? Hum Gene Ther 2015;26:779-781.
3. Buning H, Schmidt M. Adeno-associated vector toxicity - to be or not to be? Mol Ther 2015;23: 1673-1675.
4. Nault JC, Colombo M. Hepatocellular carcinoma and direct acting antiviral treatments: controversy after the revolution. J Hepatol 2016;65: 663-665.
5. Nault JC, Datta S, Imbeaud S, et al. Adenoassociated virus type 2 as an oncogenic virus in human hepatocellular carcinoma. Mol Cell Oncol 2016;3:e1095271.
6. Nault JC, Mami I, La Bella T, et al. Wild-type AAV insertions in hepatocellular carcinoma do not inform debate over genotoxicity risk of vectorized AAV. Mol Ther 2016;24:660-661.
7. Nault JC, Datta S, Imbeaud S, et al. AAV2 and hepatocellular carcinoma. Hum Gene Ther 2016; 27:211-213.
8. Park KJ, Lee J, Park JH, et al. Adeno-associated virus 2-mediated hepatocellular carcinoma is very rare in Korean patients. Ann Lab Med 2016;36: 469-474.
9. Atchison RW, Casto BC, Hammon WM. Adenovirus-associated defective virus particles. Science 1965;149:754-756.
10. Blacklow NR, Hoggan MD, Sereno MS, et al. A seroepidemiologic study of adenovirus-associated virus infection in infants and children. Am J Epidemiol 1971;94:359-366.
11. Kirschstein RL, Smith KO, Peters EA. Inhibition of adenovirus 12 oncogenicity by adeno-associated virus. Proc Soc Exp Biol Med 1968;128:670-673.
12. Mayor HD, Houlditch GS, Mumford DM. Influence of adeno-associated satellite virus on adenovirusinduced tumours in hamsters. Nat New Biol 1973; 241:44-46.
13. de la Maza LM, Carter BJ. Inhibition of adenovirus oncogenicity in hamsters by adeno-associated virus DNA. J Natl Cancer Inst 1981;67:1323-1326.
14. de la Maza LM, Carter BJ. Molecular structure of adeno-associated virus variant DNA. J Biol Chem 1980;255:3194-3203.
15. Raj K, Ogston P, Beard P. Virus-mediated killing of cells that lack p53 activity. Nature 2001;412: 914-917.
16. Vogelstein B, Kinzler KW. Achilles' heel of cancer? Nature 2001;412:865-866.
17. Casto BC, Goodheart CR. Inhibition of adenovirus transformation in vitro by AAV-1. Proc Soc Exp Biol Med 1972;140:72-78.
18. Cukor G, Blacklow NR, Kibrick S, et al. Effect of adeno-associated virus on cancer expression by herpesvirus-transformed hamster cells. J Natl Cancer Inst 1975;55:957-959.
19. Ostrove JM, Duckworth DH, Berns KI. Inhibition of adenovirus-transformed cell oncogenicity by adeno-associated virus. Virology 1981;113:521-533.
20. Katz E, Carter BJ. Effect of adeno-associated virus on transformation of NIH 3T3 cells by ras gene and on tumorigenicity of an NIH 3T3 transformed cell line. Cancer Res 1986;46:3023-3026.
21. Hermonat PL. Inhibition of H-ras expression by the adeno-associated virus Rep78 transformation suppressor gene product. Cancer Res 1991;51: 3373-3377.
22. Khleif SN, Myers T, Carter BJ, et al. Inhibition of cellular transformation by the adeno-associated virus rep gene. Virology 1991;181:738-741.
23. Mayor HD, Drake S, Stahmann J, et al. Antibodies to adeno-associated satellite virus and herpes simplex in sera from cancer patients and normal adults. Am J Obstet Gynecol 1976;126:100-104.
24. Strickler HD, Viscidi R, Escoffery C, et al. Adenoassociated virus and development of cervical neoplasia. J Med Virol 1999;59:60-65.
25. Odunsi KO, van Ee CC, Ganesan TS, et al. Evaluation of the possible protective role of adenoassociated virus type 2 infection in HPV-associated premalignant disease of the cervix. Gynecol Oncol 2000;78:342-345.
26. Coker AL, Russell RB, Bond SM, et al. Adenoassociated virus is associated with a lower risk of high-grade cervical neoplasia. Exp Mol Pathol 2001;70:83-89.
27. Meyers C, Alam S, Mane M, et al. Altered biology of adeno-associated virus type 2 and human papillomavirus during dual infection of natural host tissue. Virology 2001;287:30-39.
28. Hermonat PL, Santin AD, Zhan D. Binding of the human papillomavirus type 16 E7 oncoprotein and the adeno-associated virus Rep78 major regulatory protein in vitro and in yeast and the potential for downstream effects. J Hum Virol 2000;3: 113-124.
29. Zhan D, Santin AD, Liu Y, et al. Binding of the human papillomavirus type 16 p97 promoter by the adeno-associated virus Rep78 major regulatory protein correlates with inhibition. J Biol Chem 1999;274:31619-31624.
30. Hermonat PL, Meyers C, Parham GP, et al. Inhibition/stimulation of bovine papillomavirus by adeno-associated virus is time as well as multiplicity dependent. Virology 1998;247:240-250.
31. Hermonat PL, Plott RT, Santin AD, et al. Adenoassociated virus Rep78 inhibits oncogenic transformation of primary human keratinocytes by a human papillomavirus type 16-ras chimeric. Gynecol Oncol 1997;66:487-494.
32. Hermonat PL. Adeno-associated virus inhibits human papillomavirus type 16: a viral interaction implicated in cervical cancer. Cancer Res 1994;54: 2278-2281.
33. Hermonat PL. Inhibition of bovine papillomavirus plasmid DNA replication by adeno-associated virus. Virology 1992;189:329-333.
34. Hermonat PL. The adeno-associated virus Rep78 gene inhibits cellular transformation induced by bovine papillomavirus. Virology 1989;172:253-261.
35. Liu T, Cong M, Wang P, et al. Adeno-associated virus Rep78 protein inhibits Hepatitis B virus replication through regulation of the HBV core promoter. Biochem Biophys Res Commun 2009; 385:106-111.
36. Kokorina NA, Santin AD, Li C, et al. Involvement of protein-DNA interaction in adeno-associated virus Rep78-mediated inhibition of HIV-1. J Hum Virol 1998;1:441-450.
37. Batchu RB, Kotin RM, Hermonat PL. The regulatory rep protein of adeno-associated virus binds to sequences within the c-H-ras promoter. Cancer Lett 1994;86:23-31.
38. Hermonat PL. Down-regulation of the human c-fos and c-myc proto-oncogene promoters by adenoassociated virus Rep78. Cancer Lett 1994;81: 129-136.
39. Kotin RM, Siniscalco M, Samulski RJ, et al. Site-specific integration by adeno-associated virus. Proc Natl Acad Sci U S A 1990;87:2211-2215.
40. Kotin RM, Menninger JC, Ward DC, et al. Mapping and direct visualization of a region-specific viral DNA integration site on chromosome 19q13-qter. Genomics 1991;10:831-834.
41. Samulski RJ, Zhu X, Xiao X, et al. Targeted integration of adeno-associated virus (AAV) into human chromosome 19. EMBO J 1991;10:3941-3950.
42. Kotin RM, Linden RM, Berns KI. Characterization of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination. EMBO J 1992;11: 5071-5078.
43. Ponnazhagan S, Erikson D, Kearns WG, et al. Lack of site-specific integration of the recombinant adeno-associated virus 2 genomes in human cells. Hum Gene Ther 1997;8:275-284.
44. Kearns WG, Afione SA, Fulmer SB, et al. Recombinant adeno-associated virus (AAV-CFTR) vectors do not integrate in a site-specific fashion in an immortalized epithelial cell line. Gene Ther 1996;3:748-755.
45. Yang CC, Xiao X, Zhu X, et al. Cellular recombination pathways and viral terminal repeat hairpin structures are sufficient for adeno-associated virus integration in vivo and in vitro. J Virol 1997;71: 9231-9247.
46. Schnepp BC, Clark KR, Klemanski DL, et al. Genetic fate of recombinant adeno-associated virus vector genomes in muscle. J Virol 2003;77:3495-3504.
47. Nakai H, Storm TA, Fuess S, et al. Pathways of removal of free DNA vector ends in normal and DNAPKcs-deficient SCID mouse hepatocytes transduced with rAAV vectors. Hum Gene Ther 2003;14:871-881.
48. Donsante A, Vogler C, Muzyczka N, et al. Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors. Gene Ther 2001;8: 1343-1346.
49. Donsante A, Miller DG, Li Y, et al. AAV vector integration sites in mouse hepatocellular carcinoma. Science 2007;317:477.
50. Wang PR, Xu M, Toffanin S, et al. Induction of hepatocellular carcinoma by in vivo gene targeting. Proc Natl Acad Sci U S A 2012;109:11264-11269.
51. Zhong L, Malani N, Li M, et al. Recombinant adeno-associated virus integration sites in murine liver after ornithine transcarbamylase gene correction. Hum Gene Ther 2013;24:520-525.
52. Chandler RJ, LaFave MC, Varshney GK, et al. Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy. J Clin Invest 2015;125:870-880.
53. Rosas LE, Grieves JL, Zaraspe K, et al. Patterns of scAAV vector insertion associated with oncogenic events in a mouse model for genotoxicity. Mol Ther 2012;20:2098-2110.
54. Gauttier V, Pichard V, Aubert D, et al. No tumour-initiating risk associated with scAAV transduction in newborn rat liver. Gene Ther 2013;20:779-784.
55. Bell P, Wang L, Lebherz C, et al. No evidence for tumorigenesis of AAV vectors in a large-scale study in mice. Mol Ther 2005;12:299-306.
56. Li H, Malani N, Hamilton SR, et al. Assessing the potential for AAV vector genotoxicity in a murine model. Blood 2011;117:3311-3319.
57. Niemeyer GP, Herzog RW, Mount J, et al. Longterm correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy. Blood 2009;113:797-806.
58. Kaeppel C, Beattie SG, Fronza R, et al. A largely random AAV integration profile after LPLD gene therapy. Nat Med 2013;19:889-891.
59. Gil-Farina I, Fronza R, Kaeppel C, et al. Recombinant AAV integration is not associated with hepatic genotoxicity in nonhuman primates and patients. Mol Ther 2016;24:1100-1105.
60. Valdmanis PN, Lisowski L, Kay MA. rAAVmediated tumorigenesis: still unresolved after an AAV assault. Mol Ther 2012;20:2014-2017.
61. Russell DW, Grompe M. Adeno-associated virus finds its disease. Nat Genet 2015;47:1104-1105.
62. Ginn SL, Alexander IE. Gene therapy: progress in childhood disease. J Paediatr Child Health 2012; 48:466-471.
63. Surosky RT, Urabe M, Godwin SG, et al. Adenoassociated virus Rep proteins target DNA sequences to a unique locus in the human genome. J Virol 1997;71:7951-7959.
64. Owens RA. Second generation adeno-associated virus type 2-based gene therapy systems with the potential for preferential integration into AAVS1. Curr Gene Ther 2002;2:145-159.
65. Huttner NA, Girod A, Schnittger S, et al. Analysis of site-specific transgene integration following cotransduction with recombinant adenoassociated virus and a rep encoding plasmid. J Gene Med 2003;5:120-129.
66. Howden SE, Voullaire L, Wardan H, et al. Sitespecific, Rep-mediated integration of the intact beta-globin locus in the human erythroleukaemic cell line K562. Gene Ther 2008;15:1372-1383.
67. Daya S, Cortez N, Berns KI. Adeno-associated virus site-specific integration is mediated by proteins of the nonhomologous end-joining pathway. J Virol 2009;83:11655-11664.
68. Srivastava A. Adeno-associated virus: the naturally occurring virus versus the recombinant vector. Hum Gene Ther 2016;27:1-6.
69. Srivastava A. In vivo tissue-tropism of adenoassociated viral vectors. Curr Opin Virol 2016;21: 75-80.
70. Ling C, Li B, Ma W, et al. Development of optimized AAV serotype vectors for high-efficiency transduction at further reduced doses. Hum Gene Ther Methods 2016;27:143-149.